Guotai CSI BIOMEDICINE ETF(512290) Rises 0.91% Intraday,Institutions Confirm Clear Industry Recovery Trend

NewTimeSpace News: As of 09:33 on April 15, 2026, the CSI Biomedicine Index (930726) surged 1.05%. Constituent stocks: BeiGene rose 3.53%, Hengrui Medicine 2.94%, Allist Pharmaceuticals 2.23%, followed by gains in Beijing Tiantan Biological Products, Sinocelltech and other stocks.Guotai CSI BIOMEDICINE ETF(512290) rose 0.91% to 1.0 yuan. Over the longer term, as of April 14, 2026, the ETF had climbed 1.86% cumulatively in the past week. (Stocks listed above are index constituents only, no specific recommendation implied.)

In terms of liquidity,Guotai CSI BIOMEDICINE ETFposted an intraday turnover rate of 0.6% and trading volume of 22.6537 million yuan. As of April 14, its average daily trading volume in the past month reached 89.7062 million yuan.

In terms of size, the latest scale of the ETF reached 3.699 billion yuan. (Data source: Wind)

Data showed that leveraged capital continued to allocate. The latest margin purchase amount reached 6.6850 million yuan, and the latest margin balance stood at 131 million yuan. (Data source: Wind)

As of April 14, the ETF’s net value rose 9.91% over the past year.

In terms of profitability, since inception as of April 14, 2026, the ETF had a maximum single-month return of 23.26%, a longest winning streak of 8 months with a cumulative gain of 109.28%, and an average return of 6.56% in rising months. It had outperformed its benchmark by an annualized return of 2.51% since inception.

In terms of drawdown, since the beginning of the year, the relative drawdown versus its benchmark was 0.11% as of April 14.

In terms of fees, the management fee rate is 0.50% and the custody fee rate is 0.10%.

In terms of tracking accuracy, as of April 14, 2026, the ETF’s tracking error over the past month was 0.004%.

Guotai CSI BIOMEDICINE ETFclosely tracks the CSI Biomedicine Index, which selects listed companies providing cell therapy, gene sequencing, blood products, biotech drugs, vaccines, in vitro diagnostics and other related products and services as index samples to reflect the overall performance of biomedical listed securities.

Data showed that as of March 31, 2026, the top 10 weighted stocks of the CSI Biomedicine Index (930726) were WuXi AppTec, Hengrui Medicine, Mindray Medical, Shanghai RAAS Blood Products, Changchun High-Tech, BeiGene, Allist Pharmaceuticals, Gan Lee Pharmaceuticals, Rongchang Bio, and Asymchem Laboratories. The top 10 weighted stocks accounted for 67.83% in total. (Stocks listed above are index constituents only, no specific recommendation implied.)

China Post Securities stated that the overall industry recovery is clear and prosperity continues to rise. CDMO guidance is optimistic, while pre-clinical and clinical CRO sectors have also seen clear order recovery, which will gradually translate into performance.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.